News

VEC-162 demonstrated statistically significant improvements at all three tested doses compared to placebo in the primary endpoint of the trial, sleep onset. VEC-162 was also demonstrated to be

The FDA has asked a panel of outside experts to discuss the overall risks and benefits of the antibiotic Ketek during a meeting in December, according to a

The study was designed to evaluate the safety and effectiveness of topical interferon alpha-2b in patients with cytologically confirmed low-grade squamous intraepithelial lesions and human papilloma virus infection

“In the statistical plan, a total of 364 patients would be required to obtain 90% power with a 30% allowance for drop out,” said Randall Kaye, vice president

“We are pleased that the FDA has agreed to remove the clinical hold status of the trials, and we plan to continue to work closely with UCB to

Fresenius has paid Nabi Biopharmaceuticals $65 million in cash and will pay an additional $20 million upon the successful completion of certain milestones. Fresenius has also acquired rights

Canada’s generic drug makers argue that the ban could prevent customers’ access to cheaper generic drugs and be costly for Canada’s healthcare system. “Canada’s Parliament approved legislation allowing

The companies have been awarded 180-day exclusivity for their copies of Zocor, with no rival drugs allowed to be marketed during this period. As the first company to

The trial evaluated 3% NanoEmulsion diclofenac topical cream. The analysis of the data indicates the formulation was safe with no serious adverse events. In addition, the pharmacokinetic analysis